Common and Specific Associations of Anti-SSA/Ro60 and Anti-Ro52/TRIM21 Antibodies in Systemic Lupus Erythematosus
Table 2
Association of anti-SSA/Ro60 and anti-Ro52/TRIM21 with clinical manifestations in SLE.
141 patients
Anti-SSA/Ro60 ()
Anti-Ro52/TRIM21 ()
Clinical manifestations
%
%
OR (95% CI)
%
OR (95% CI)
Malar rash
88
62.4
38
63.3
0.82 (0.33–2.08)
26
66.7
1.68 (0.59–4.76)
Discoid lesions
29
20.6
13
21.7
1.13 (0.38–3.39)
7
17.9
0.69 (0.20–2.41)
Photosensitivitya
89
63.1
45
75.0
1.66 (0.64–4.29)
31
79.5
1.90 (0.62–5.87)
Oral ulcers
78
55.3
31
51.7
0.45 (0.17–1.16)
24
61.5
2.54 (0.88–7.38)
Nonscarring alopeciab
75
53.2
32
53.3
0.58 (0.21–1.56)
23
59.0
1.09 (0.35–3.73)
Arthritisc
118
83.7
49
81.7
1.50 (0.37–6.09)
31
79.5
0.98 (0.22–4.33)
Serositis
28
19.8
12
20.0
1.11 (0.37–3.37)
7
17.9
0.88 (0.25–3.12)
Renal involvementd
45
31.9
21
35.0
1.21 (0.45–3.29)
13
33.3
1.33 (0.44–4.06)
Neurologic disordere
23
16.3
11
18.3
1.60 (0.47–5.42)
7
17.9
0.95 (0.25–3.58)
Xerophthalmia/xerostomia
37
26.2
22
36.7
1.86 (0.65–5.33)
16
41.0
1.69 (0.56–5.05)
Raynaud’s phenomenonf
67
47.5
33
55.0
1.04 (0.41–2.61)
24
61.5
2.42 (0.86–6.84)
Neurologic disorder
23
16.3
11
18.3
1.31 (0.41–4.25)
7
17.9
0.98 (0.27–3.58)
Cytopenia
88
62.4
39
66.7
0.67 (0.27–1.66)
29
74.3
2.92 (1.01–8.48)
g
Leukopenia or lymphopenia
77
54.6
36
60.0
1.08 (0.44–2.64)
25
64.1
1.74 (0.63–4.78)
Thrombocytopeniah
18
12.8
4
6.7
4
10.2
Haemolytic anaemiah
5
3.5
2
3.3
3
7.7
Anti-SSA/Ro60 and anti-Ro52/TRIM21 analyzed together as independent variables by binary logistic regression analysis adjusted for sex and age (at diagnosis and time of analysis). Other autoantibodies also included as independent variable after selection by forward step procedure: aanti-dsDNA (negative association), banti-SS-B (positive association), canti-SSB (negative association), danti-dsDNA (positive association), eanti-cardiolipin (positive association), fanti-RNP (positive association), g, and hnot statistically analysed.
